Trial Profile
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT3, GT4, GT5, and GT6 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Grazoprevir (Primary) ; Grazoprevir/ruzasvir/uprifosbuvir (Primary) ; Ruzasvir (Primary) ; Uprifosbuvir (Primary) ; Elbasvir; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms C-CREST 2
- Sponsors Merck Sharp & Dohme
- 03 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 04 Jan 2017 This trial was completed in Denmark, according to European Clinical Trials Database.